摘要
目的探讨阿昔洛韦抗病毒联合脾氨肽(脾氨肽口服冻干粉)免疫调节剂治疗儿童传染性单核细胞增多症(IM)的有效性。方法选取2015-08~2017-05在该院住院的IM患儿56例,随机分为两组各28例,对照组给予阿昔洛韦抗病毒及对症等常规治疗;观察组在对照组的基础上加用细胞免疫调节剂脾氨肽治疗,疗程2周。观察两组患儿临床疗效、临床症状改善情况以及T淋巴细胞亚群的变化情况。结果观察组临床疗效优于对照组,差异有统计学学意义(P<0.05),但观察组临床症状、体征消退时间以及住院时间较对照组短(P均<0.05),治疗后两组患儿CD3+细胞水平、CD8+细胞水平降低,CD4+细胞水平及CD4+/CD8+明显升高,差异有统计学意义(P<0.05),且观察组变化水平更显著(P<0.05)。结论阿昔洛韦联合脾氨肽治疗IM的临床疗效优于单纯使用阿昔洛韦,临床疗效显著及安全性更好,值得基层临床推广应用。
Objective To investigate the clinical study of acyclovir combined with spleen aminopeptide（oral freeze-dried powder） immunomodulator on infectious mononucleosis（IM） in children. Methods 56 patients with IM were randomly divided into two groups, with 28 cases in each group. The control group was treated with acyclovir for antivirus and symptomatic treatment for 2 weeks. The observation group was treated with a cellular immunomodulator spleen aminopeptide plus the same treatment as the control group. The clinical effect, improvement of clinical symptoms and the changes of T lymphocyte subsets were compared between the two groups. Results The clinical effect of the observation group was better than that of the control group（P〈0.05）. The time for improvement of the clinical symptoms and the signs recovery time, and the time for hospital stay in the observation group was significantly shorter than that in the control group（P〈0.05）. Compared with those before treatment, the levels of CD3＋ cells and CD8＋ cells were significantly lower and the levels of CD4＋ cells and CD4＋/ CD8＋ were significantly higher in both of the two groups after treatment（P〈0.05）, however the improvements of these indexes in the observation group were better than those in the control group（P〈0.05）. Conclusion Acyclovir combined with spleen aminopeptide is safer and more effective than acyclovir alone in treatment of IM in children.
作者
郭瑜
黄东辉
蔡伟霞
GUO Yu;HUANG Dong-hui;CAI Wei-xia(Department of Paediatrics,Qiaotou Hospital of Dongguan City,Guangdong 523523,Chin)
出处
《中国临床新医学》
2018年第8期765-768,共4页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金
东莞市社会科技发展(一般)项目(编号:201750715036255)
